| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/100-1/500 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | cell death activator CIDE-B; cell death-inducing DFFA-like effector B; |
| Entrez GeneID | 27141; |
| WB Predicted band size | 24kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | Synthesized peptide derived from internal of human CIDEB. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于CIDEB抗体的3篇文献摘要示例(注：以下内容为模拟生成，仅供参考)：
---
1. **文献名称**: *CIDEB mediates lipid droplet fusion in hepatocytes through interaction with apolipoprotein A-IV*
**作者**: Li, Y. et al. (2018)
**摘要**: 本研究利用CIDEB特异性抗体，通过免疫荧光和Western blot技术，证实CIDEB通过结合载脂蛋白A-IV调控肝细胞脂滴融合，其表达缺失导致小鼠肝脏脂质蓄积异常。
2. **文献名称**: *Role of CIDEB in non-alcoholic fatty liver disease progression revealed by antibody-based inhibition*
**作者**: Zhang, R. et al. (2020)
**摘要**: 作者使用CIDEB中和抗体阻断其功能，发现CIDEB活性抑制会加剧高脂饮食小鼠的肝脏炎症和纤维化，提示其在非酒精性脂肪肝中具有保护作用。
3. **文献名称**: *CIDEB antibody validation in human adipose tissue: Implications for obesity-related metabolic dysfunction*
**作者**: Wang, L. et al. (2019)
**摘要**: 通过CIDEB抗体的免疫组化分析，研究发现肥胖患者脂肪组织中CIDEB表达显著下调，且与胰岛素抵抗相关，提示其参与能量代谢调控。
---
(注：实际文献需通过PubMed/Google Scholar等平台检索确认。)
The CIDEB (Cell Death-Inducing DFFA-like Effector B) antibody is a research tool targeting the CIDEB protein, a member of the CIDE (Cell Death-Inducing DFF45-like Effector) family. CIDEB proteins are primarily involved in regulating lipid metabolism and apoptosis. They play a critical role in lipid droplet (LD) formation, fusion, and lipid storage in hepatocytes and adipocytes. CIDEB is highly expressed in the liver and adipose tissues, where it facilitates LD growth by promoting lipid transfer between droplets, impacting energy homeostasis and metabolic health. Dysregulation of CIDEB is linked to metabolic disorders, including non-alcoholic fatty liver disease (NAFLD), obesity, and insulin resistance.
CIDEB antibodies are widely used in biochemical assays (e.g., Western blot, immunofluorescence, immunohistochemistry) to study protein expression, localization, and function. Researchers employ these antibodies to explore CIDEB's role in lipid metabolism pathways, its interaction with other LD-associated proteins (e.g., perilipin, ATGL), and its contribution to diseases like hepatic steatosis or viral hepatitis (CIDEB is a host factor for hepatitis C virus entry). Recent studies also investigate CIDEB's potential as a therapeutic target for metabolic syndrome or cancer, given its dual role in lipid regulation and apoptosis. Validated CIDEB antibodies are essential for elucidating molecular mechanisms in metabolic research and drug development.
×
